ANIX

Anixa Biosciences Inc

2.95

Oct 05 • 3:59 PM ET 0.00 (0.00%)

2.99

Aftermarket • 7:52 PM ET +0.04 (1.28%)

Healthcare Biotechnology USA Micro NASD

Oct 05, 8:20 AMAnixa Biosciences sees first three-month stable disease in Phase 1 FSHR CAR-T ovarian cancer trial, with no dose-limiting toxicities at top dose

Peers: COYA CYPH INO LONA NRXS ATYR CGTX KLRS NRXP KALA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	102.55M
Enterprise Value	87.59M
Income	-10.38M
Sales	0.00M
Book/sh	0.42
Cash/sh	0.40
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	Oct 07, 1983

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.05
P/C	7.40
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.54
Current Ratio	8.54
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-0.31
EPS next Y	-0.32
EPS next Q	-0.08
EPS this Y	6.35%
EPS next Y	-1.08%
EPS next 5Y	0.29%
EPS past 3/5Y	9.05% 5.67%
Sales past 3/5Y	- -
EPS Y/Y TTM	10.04%
Sales Y/Y TTM	-
EPS Q/Q	-9.64%
Sales Q/Q	-
Earnings	Sep 11
EPS/Sales Surpr.	0.00% -

Insider Own	5.74%
Insider Trans	8.09%
Inst Own	15.38%
Inst Trans	1.06%
ROA	-63.45%
ROE	-66.84%
ROIC	-71.11%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	5.55%
SMA50	-6.81%
SMA200	-1.68%
Trades

Shs Outstand	34.58M
Shs Float	32.77M
Short Float	3.22%
Short Ratio	3.57
Short Interest	1.05M
52W High	5.46 -45.94%
52W Low	2.32 27.16%
Volatility	5.44% 5.54%
ATR (14)	0.17
RSI (14)	50.60
Beta	0.49
Rel Volume	1.25
Avg Volume	295.85K
Volume	369,463

Perf Week	5.73%
Perf Month	-3.28%
Perf Quarter	-0.34%
Perf Half Y	13.90%
Perf YTD	-5.45%
Perf Year	-9.79%
Perf 3Y	-18.96%
Perf 5Y	-35.02%
Perf 10Y	-37.89%
Recom	1.00
Target Price	7.50
Prev Close	2.95
Price	2.95
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-21-25	Initiated	Maxim Group	Buy	$10
Dec-23-22	Initiated	Chardan Capital Markets	Buy	$8
Apr-12-21	Initiated	H.C. Wainwright	Buy	$11

Oct-05-26 08:15AM	Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Oct-01-26 08:35AM	Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial (PR Newswire) -5.46%
Sep-21-26 08:45AM	Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 (PR Newswire)
Sep-16-26 09:15AM	Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board (PR Newswire)
Sep-09-26 08:35AM	Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV (PR Newswire)
08:00AM	Loading…
Sep-03-26 08:00AM	Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 (PR Newswire)
Aug-24-26 08:55AM	Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy (PR Newswire)
Aug-18-26 08:45AM	Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
Jul-14-26 08:33AM	Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology (PR Newswire)
Jul-06-26 08:30AM	Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date (PR Newswire) -6.73%
Jun-30-26 06:35AM	Anixa Biosciences secures Korean patent for breast cancer vaccine (Pharmaceutical Business Review)
Jun-29-26 08:45AM	Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 (PR Newswire)
Jun-26-26 09:10AM	Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium (PR Newswire) +6.49%
Jun-11-26 09:05AM	Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium (PR Newswire) +5.53%
Jun-01-26 09:00AM	Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance (PR Newswire)
08:55AM	Loading…
May-11-26 08:55AM	Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy (PR Newswire)
May-01-26 09:15AM	Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV (PR Newswire)
Apr-29-26 09:10AM	Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Apr-22-26 08:45AM	Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting (PR Newswire) +9.03%
Apr-09-26 09:05AM	Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 (PR Newswire)
Apr-07-26 08:55AM	Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 (PR Newswire)
Apr-06-26 09:10AM	Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs (PR Newswire)
Apr-01-26 08:50AM	Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing (PR Newswire) +5.43%
Mar-30-26 09:05AM	Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer (PR Newswire)
Mar-12-26 10:38AM	Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast (PR Newswire)
Mar-09-26 08:30AM	Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Mar-02-26 09:10AM	Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress (PR Newswire)
Feb-23-26 08:55AM	Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat (PR Newswire)
Feb-10-26 03:50PM	Anixa Biosciences CEO Calls 2026 Pivotal as Breast Cancer Vaccine, Ovarian CAR-T Advance (MarketBeat)
Feb-09-26 08:00AM	Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation (PR Newswire)
07:31AM	Loading…
07:31AM	EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues (Benzinga)
Feb-02-26 09:00AM	Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization (PR Newswire)
Jan-27-26 08:30AM	Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Dec-15-25 08:45AM	Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic (PR Newswire) -8.94%
Dec-10-25 09:00AM	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 (PR Newswire)
Nov-17-25 08:15AM	Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization (PR Newswire)
Nov-12-25 09:00AM	Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s (PR Newswire)
Nov-10-25 10:30AM	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 (PR Newswire)
Nov-05-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:55AM	Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic (PR Newswire)
Oct-23-25 08:45AM	Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference (PR Newswire)
Oct-20-25 08:25AM	Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Oct-17-25 12:00PM	Are You Looking for a Top Momentum Pick? Why ANIXA BIOSCIENCES INC (ANIX) is a Great Choice (Zacks) -6.82%
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire) +8.03%
Oct-07-25 08:30AM	Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial (PR Newswire) +26.46%
Oct-02-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
Sep-22-25 08:05AM	Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium (PR Newswire) +5.76%
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
09:40AM	Is Solventum Corporation (SOLV) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-09-25 06:45PM	3 Under-the-Radar Biotechs Under $5 That Could Soar 200% (MarketBeat)
Sep-08-25 08:00AM	Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival (PR Newswire)
Sep-02-25 08:54AM	Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-25-25 09:13AM	Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-20-25 08:37AM	Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Aug-18-25 09:00AM	Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Aug-12-25 08:05AM	Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology (PR Newswire)
Aug-08-25 09:15AM	Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference (PR Newswire)
Aug-04-25 08:45AM	Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial (PR Newswire) +8.31%
Jul-30-25 08:15AM	Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Jul-25-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-24-25 08:00AM	Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s (PR Newswire)
Jul-09-25 09:40AM	Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology (PR Newswire)
Jun-26-25 12:00PM	ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy? (Zacks)
Jun-23-25 09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks)
08:00AM	Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Jun-20-25 07:30AM	Anixa Biosciences to Host an Investor Webcast on June 26, 2025 (PR Newswire)
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire) +5.42%
Jun-10-25 12:00PM	What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now? (Zacks)
07:00AM	Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage (PR Newswire)
Jun-09-25 08:00AM	Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 (PR Newswire) +23.19%
Jun-05-25 12:00PM	All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy (Zacks)
09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks)
Jun-03-25 07:25AM	Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview (PR Newswire)
Jun-02-25 07:00AM	Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine (PR Newswire) +12.45%
May-19-25 08:00AM	Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones (PR Newswire)
May-12-25 08:00AM	Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
Apr-30-25 08:00AM	Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th (PR Newswire)
Apr-14-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio (PR Newswire)
Apr-11-25 09:40AM	Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-10-25 09:58AM	ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up (Zacks)
Apr-09-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology (PR Newswire) +13.03%
07:45AM	EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent (Benzinga)
Apr-01-25 08:00AM	Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th (PR Newswire)
Mar-25-25 08:00AM	Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines (PR Newswire)
07:51AM	EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines (Benzinga)
Mar-24-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine (PR Newswire)
07:46AM	EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine (Benzinga)
Mar-17-25 08:00AM	Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th (PR Newswire)
Mar-10-25 08:30AM	Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties (PR Newswire) -7.39%
Mar-03-25 08:00AM	Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th (PR Newswire) -9.84%
Feb-26-25 08:00AM	Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Feb-25-25 07:30AM	Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' 'America Reports' (PR Newswire)
Feb-24-25 08:00AM	Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer (PR Newswire) -6.49%
Feb-18-25 08:00AM	Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Feb-14-25 07:00AM	Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview (PR Newswire)
Feb-11-25 08:30AM	Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum (PR Newswire)
Feb-04-25 08:30AM	Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention (PR Newswire) +6.07%
Jan-21-25 08:30AM	Anixa Biosciences CEO Provides Letter to Shareholders (PR Newswire) +16.60%
Dec-06-24 08:30AM	iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024 (ACCESS Newswire)

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The Other segment refers to its legacy operations, including patent licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

PhDAmit D. Kumar

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Catelani Michael	President, COO, & CFO	Sep 30 '26	Buy	2.84	5,500	15,620	50,000	Sep 30 10:25 AM
KUMAR AMIT	Chief Executive Officer	Sep 24 '26	Buy	2.78	7,000	19,460	672,000	Sep 28 08:45 AM
Baskies Arnold M	Director	Sep 24 '26	Buy	2.76	5,000	13,800	140,572	Sep 28 08:30 AM
Titterton Lewis H jr	Director	Sep 23 '26	Buy	2.69	49,036	131,907	1,046,003	Sep 25 08:39 AM
KUMAR AMIT	Chief Executive Officer	Sep 10 '26	Buy	2.75	3,000	8,250	665,000	Sep 14 09:45 AM
Titterton Lewis H jr	Director	Sep 10 '26	Buy	2.73	10,000	27,300	996,967	Sep 14 09:15 AM
KUMAR AMIT	Chief Executive Officer	Sep 10 '26	Buy	2.76	5,000	13,800	662,000	Sep 11 08:00 AM
KUMAR AMIT	Chief Executive Officer	Jul 31 '26	Buy	3.47	5,000	17,350	657,000	Aug 03 08:45 AM
Baskies Arnold M	Director	Jul 27 '26	Option Exercise	3.13	6,000	18,780	141,000	Jul 29 09:14 AM
KUMAR AMIT	Chief Executive Officer	Jul 27 '26	Buy	3.44	5,000	17,200	652,000	Jul 28 10:20 AM
KUMAR AMIT	Chief Executive Officer	Jul 27 '26	Buy	3.37	3,188	10,744	647,000	Jul 27 03:25 PM
KUMAR AMIT	Chief Executive Officer	Jul 24 '26	Buy	3.73	3,000	11,190	643,812	Jul 27 09:00 AM
KUMAR AMIT	Chief Executive Officer	Jul 20 '26	Buy	3.46	5,000	17,300	640,812	Jul 21 10:23 AM
Titterton Lewis H jr	Director	Jul 20 '26	Buy	3.47	12,000	41,640	986,967	Jul 20 06:19 PM
Titterton Lewis H jr	Director	Jul 15 '26	Buy	3.28	2,797	9,174	974,967	Jul 16 09:00 AM
KUMAR AMIT	Chief Executive Officer	Jul 10 '26	Buy	3.04	5,000	15,200	635,812	Jul 13 08:59 AM
Titterton Lewis H jr	Director	Jun 16 '26	Buy	2.64	2,836	7,487	972,170	Jun 17 11:21 AM
KUMAR AMIT	Chief Executive Officer	Jun 12 '26	Buy	2.50	21,000	52,500	630,812	Jun 16 09:00 AM
Baskies Arnold M	Director	Jan 28 '26	Buy	3.04	10,000	30,400	135,000	Jan 29 08:58 AM
Titterton Lewis H jr	Director	Dec 15 '25	Option Exercise	2.92	16,000	46,720	969,334	Dec 16 08:56 AM
KUMAR AMIT	Chief Executive Officer	Oct 30 '25	Option Exercise	2.92	200,000	584,000	779,925	Oct 31 09:13 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANIX

Anixa Biosciences Inc

Upgrade your Finviz experience